Tag: Spineway
Spineway growing by 28% in the 1st quarter – 04/17/2024 at 10:06 a.m.
(AOF) – Spineway achieved a turnover of 3.1 million euros in the first quarter of 2024, an increase of 28%. The specialist in innovative implants for the treatment of severe…
Spineway finalizes its share consolidation
(AOF) – Spineway announces the finalization of the consolidation operation of its shares by exchange of 1 new share with a par value of 4 euros for 2,000 old shares…
Spineway: General meeting convened
A.S. Published on 02/19/2024 at 6:44 p.m. (Boursier.com) — Spineway informs its shareholders that they are…
Spineway widens its losses in 2023 but remains confident – 02/07/2024 at 6:15 p.m.
(AOF) – Spineway announces having achieved a turnover of 10.5 million euros in 2023, an increase of 42% compared to 2022. The medtech specifies that the gross margin is “maintained”…
Spineway widens its losses in 2023 but remains confident
(AOF) – Spineway announces having achieved a turnover of 10.5 million euros in 2023, an increase of 42% compared to 2022. The medtech specifies that the gross margin is “maintained”…
Spineway: sharp increase in activity in 2023 – 01/26/2024 at 12:21 p.m.
(CercleFinance.com) – Spineway saw its turnover increase by 42% in 2023, a year that the manufacturer of implants and surgical instruments considers to be a good commercial exercise given the…
Spineway: share consolidation planned for February 27
By Olivier Cheilan Published on 01/05/2024 at 6:16 p.m. (Boursier.com) — The specialist in implants for the treatment…
Spineway: launch of a share consolidation – 01/05/2024 at 6:25 p.m.
(AOF) – Spineway, specialist in innovative implants for the treatment of severe spinal pathologies (spine), has decided to implement a consolidation of the shares making up its share capital, at…
Spineway: launch of a share consolidation
(AOF) – Spineway, specialist in innovative implants for the treatment of severe spinal pathologies (spine), has decided to implement a consolidation of the shares making up its share capital, at…
Spineway: FDA authorizes VEO spinal fixation system
(AOF) – The Spineway Group announces the recent 510(k) clearance from the United States Food and Drug Administration (FDA) for its VEO posterior spinal fixation system. The specialist in innovative…
Spineway: the FDA authorizes the VEO spinal fixation system – 10/19/2023 at 6:17 p.m.
(AOF) – The Spineway Group announces the recent 510(k) clearance from the United States Food and Drug Administration (FDA) for its VEO posterior spinal fixation system. The specialist in innovative…
Spineway: 8% drop in quarterly turnover – 10/13/2023 at 6:26 p.m.
(AOF) – Spineway totals a turnover of 2.1 million euros for the 3rd quarter of 2023, compared to 2.24 million in 2022, a drop of 8%. This brings 9-month activity…